Cargando…
The new era of add-on asthma treatments: where do we stand?
Globally, a small proportion (5–12%) of asthma patients are estimated to have severe disease. However, severe asthma accounts for disproportionately high healthcare resource utilization. The Global Initiative for Asthma (GINA) management committee recommends treating patients with asthma with inhale...
Autores principales: | Calhoun, William J., Chupp, Geoffrey L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124422/ https://www.ncbi.nlm.nih.gov/pubmed/35598022 http://dx.doi.org/10.1186/s13223-022-00676-0 |
Ejemplares similares
-
Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013) -
Diet Modifications in Primary Prevention of Asthma. Where Do We Stand?
por: Sozańska, Barbara, et al.
Publicado: (2021) -
Current Melanoma Treatments: Where Do We Stand?
por: Moreira, Alvaro, et al.
Publicado: (2021) -
ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011) -
Where Do We Stand?
Publicado: (1891)